Follow-On Biologics Guidance Delayed, Agency Tells BIO
This article was originally published in The Pink Sheet Daily
Executive Summary
Broad scope and broad "interest" in the topic mean it will take FDA longer than expected to complete work on the highly anticipated guidance, Acting Deputy Commissioner Woodcock says. The guidance will include an "inventory" of different ways protein products have been regulated by the agency.
You may also be interested in...
FDA Follow-On Biologics Public Meeting Slated For Early 2005
Projected timing of the meeting suggests that release of a draft guidance will not occur until at least a year after FDA’s original projected timeframe of spring 2004.
FDA Follow-On Biologics Public Meeting Slated For Early 2005
Projected timing of the meeting suggests that release of a draft guidance will not occur until at least a year after FDA’s original projected timeframe of spring 2004.
FDA Follow-On Biologics Guidance Will Follow Public Workshop, Agency Tells Senate Committee
A public scientific workshop is planned for late summer; timing or content of a guidance cannot be predicted until after the meeting, Acting Commissioner Crawford tells Senate Judiciary Committee. Sen. Schumer expresses concern that progress towards "generic" biologics is "slowing."